Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + platinum-based chemotherapy + focal radiotherapy
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This investigational combination therapy regimen consists of tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody, administered in conjunction with platinum-based chemotherapy and focal radiotherapy. Tislelizumab, developed by BeiGene, is specifically engineered to minimize binding to Fcγ receptors on macrophages, a design intended to prevent antibody-dependent cellular phagocytosis (ADCP) of T cells and potentially enhance anti-tumor activity. The regimen is currently being evaluated in a Phase II clinical trial at Fujian Cancer Hospital as a postoperative adjuvant treatment for patients with high-risk stage III N2 non-small cell lung cancer (NSCLC). The combination aims to leverage the systemic immune-potentiating effects of PD-1 blockade, the cytotoxic effects of platinum-based chemotherapy, and the localized tumor control provided by focal radiotherapy to improve progression-free and overall survival in this patient population.
- Other names
- tislelizumab + platinum-based chemotherapy + focal radiotherapy-Fujian Cancer Hospital-non-small cell lung cancer
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DNA
Beyond the preview
Go deeper on tislelizumab + platinum-based chemotherapy + focal radiotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + platinum-based chemotherapy + focal radiotherapy.